The effect of magnesium sulphate on rocuronium action

Influence of magnesium sulphate on rocuronium pharmacodynamics - randomized control trial - :

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

REBEC

Registry ID

RBR-79j38k

Enrollment

Unknown

Registered

2020-08-14

Start date

2018-09-01

Completion date

Unknown

Last updated

2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adjuvants, anesthesia

Interventions

Experimental group: 35 women will receive magnesium sulfate (30mg/kg). Control group: 35 women will receive placebo inert solution. The magnesium sulfate will be administered randomizidely.

Drug

D04.210.500.054.040.783

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Elective surgeries under general anesthesia; needing neuromuscular blocker; ASA 1 and 2

Exclusion criteria

Exclusion criteria: Neuromuscular diseases; BMI higher than 35 or smaller than 18.5 Kg.m2; peripheral temperature smaller than 32 degrees; indicative signs in performing laryngoscopy and tracheal intubation; kidney and liver disease; hydroelectrolytic desorders and base acids; use of drugs that act in JNM; difficulty acessing the ulnar nerve; hypersensitivity to drugs used; gastroesophageal reflux.

Design outcomes

Primary

Measure	Time frame
Magnesium sulfate administered prior to induction of general anesthesia is expected to enhance the pharmacodynamic effects of rocuronium	—

Secondary

Measure	Time frame
Rocuronium latency: time interval in seconds, between the start of rocuronium injection and the reduction of 75% or more in the amplitude of contractile responses of the adductor pollicis muscle, to isolated stimuli, at that momente, laryngoscopy and tracheal intubation maneuvers were performed; ;Rocuronium clinical duration (DC 25%), time in minutes between the injection of rocuronium intubation dose and the spontaneous recovery of 25% from the first response (T1) to the sequence of 4 stimuli in adductor T4:T1 (90%) time in minutes between rocuronium injection and spontaneous recovery of TOF ratio (90%) following 4 stimuli in the adductor pollicis; ;Time for T4 recovery: time in minutes beteween rocuronium injection and spontaneous recovery of the TOF ratio (90%) the sequence of four stimulus in adductor pollicis;;Clinical conditions of tracheal intubation;	—

Measure

Time frame

Rocuronium latency: time interval in seconds, between the start of rocuronium injection and the reduction of 75% or more in the amplitude of contractile responses of the adductor pollicis muscle, to isolated stimuli, at that momente, laryngoscopy and tracheal intubation maneuvers were performed; ;Rocuronium clinical duration (DC 25%), time in minutes between the injection of rocuronium intubation dose and the spontaneous recovery of 25% from the first response (T1) to the sequence of 4 stimuli in adductor T4:T1 (90%) time in minutes between rocuronium injection and spontaneous recovery of TOF ratio (90%) following 4 stimuli in the adductor pollicis; ;Time for T4 recovery: time in minutes beteween rocuronium injection and spontaneous recovery of the TOF ratio (90%) the sequence of four stimulus in adductor pollicis;;Clinical conditions of tracheal intubation;

—

Countries

Brazil

Contacts

Public ContactAngélica Braga

Universidade Estadual de Campinas

franklinbraga@terra.com.br+55 019 35219560

Outcome results

None listed

Source: REBEC (via WHO ICTRP)